Franklin Biolabs Achieves CLIA Certification for AAV NAb Testing
Learn more
Gene Synthesis and Codon Optimization for Optimal RNA Payloads
EXECUTIVE SUMMARY
Gene Synthesis and Codon Optimization for RNA Therapeutics Payloads
CELL & GENE | RNA | BIOLOGICS
The design of an RNA payload is a primary determinant of therapeutic efficacy and safety. Beyond simple protein coding, the nucleotide sequence dictates expression levels, stability, and the potential for innate immune activation. Gene synthesis and codon optimization are direct inputs for minimizing clinical risk for RNA therapeutics. This involves a multi-parameter approach that balances maximal protein expression with sequence stability and reduced immunogenicity, tailored to the specific lipid nanoparticle (LNP) delivery system and target indication.
Frequently Asked Questions
How does codon optimization for RNA therapeutics impact the timeline for IND-enabling toxicology studies?
A well-optimized RNA payload directly accelerates IND timelines by increasing the probability of achieving desired protein expression levels in vivo. This reduces the need for costly and time-consuming dose escalation studies. By engineering sequences to avoid known immunogenic motifs, we also minimize the risk of adverse events in preclinical models, leading to a more predictable and streamlined path toward filing.
What is the interplay between the RNA payload sequence and the choice of a lipid nanoparticle (LNP) delivery system?
The RNA sequence and the LNP formulation are codependent. The physical and chemical properties of the RNA, such as length and secondary structure, can influence encapsulation efficiency and particle stability. Our approach considers this synergy from the outset, designing payloads that are compatible with advanced delivery platforms, including novel degradable lipids, to ensure efficient in vivo delivery and organ-specific targeting.
For a global clinical strategy, how do you approach payload design to meet multi-jurisdictional regulatory expectations?
We design and document the entire gene synthesis and optimization process with global submissions in mind. This includes providing a comprehensive rationale for sequence modifications and codon selection that aligns with harmonized international guidelines (ICH). The goal is to generate a single, robust data package that can support parallel IND, CTA, and IMPD submissions to agencies like the FDA and MHRA.
Payload Design for Next-Generation RNA Therapeutics
The therapeutic potential of an RNA construct is encoded directly in its nucleotide sequence. While the primary goal is to produce a functional protein, the specific codons used to write that message have a profound impact on translational efficiency and the ultimate biological outcome. An improperly optimized sequence can lead to poor protein expression, rapid degradation, or unintended immune responses, compromising an entire program before it reaches preclinical evaluation.
Our approach to payload engineering is built on an understanding of gene expression mechanics, informed by decades of work in viral vectorology. Foundational studies in AAV vectors demonstrated that codon optimization often has a more significant impact on in vivo protein expression than modifications to the vector backbone itself (PMID: 27903094). This core principle directly translates to synthetic RNA, where optimizing codon usage for the target expression system is a primary determinant of success.
Balancing Expression, Stability, and Immunogenicity
Maximizing protein expression is only one part of the equation. A multi-parameter optimization strategy is required to develop a therapeutic candidate with a viable clinical profile.
Key optimization parameters include:
-
Codon Usage Bias: Adapting the sequence to match the tRNA abundance of human cells to maximize the rate and fidelity of protein translation.
-
GC Content: Modulating GC content to enhance mRNA stability and prevent the formation of secondary structures that can impede ribosomal scanning.
-
Cryptic Splice Site Removal: Scanning for and eliminating sequence motifs that could lead to unintended splicing and the production of truncated, non-functional proteins.
-
Innate Immune Motif Avoidance: Identifying and removing specific nucleotide patterns known to trigger pattern recognition receptors like RIG-I and Toll-like receptors, thereby minimizing unintended inflammatory responses.
This process creates a synthetic construct engineered for high-fidelity expression and a quiet immunological footprint, which is a requirement for programs involving repeat dosing.
Synergy with Advanced Delivery Platforms
An optimized RNA payload must function in concert with its delivery vehicle. The development of novel, degradable lipid formulations for LNP systems has enabled more versatile and targeted in vivo delivery (PMID: 38982196). The design of the RNA payload must complement these advances. We ensure that the final construct is optimized for efficient encapsulation and protection within the LNP, facilitating its journey from the point of administration to the target cell’s cytoplasm. This integrated strategy, which aligns payload design with delivery system chemistry, is fundamental to achieving the 18-24 month IND timelines our clients require.
All construct design and synthesis activities are performed within our >100,000 sq ft facilities, which support the full lifecycle from initial plasmid generation to GxP-compliant analytics.
This rigorous, data-driven approach to gene synthesis and optimization provides the robust basis for a successful RNA therapeutic program. This work is a component that has enabled our core scientific team to contribute to a 100% successful IND rate since 2019, a track record established prior to the formal launch of Franklin Biolabs in 2024.
For more information on our comprehensive analytical and manufacturing capabilities, please see our core Vector | CMC | Analytics Services page.
This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.